Home
About Oasmia
Human Health
Animal Health
Investor Relations
Media Contact
Work at Oasmia
Home
·
Contact
·
Dictionary
·
Sitemap
Sitemap
Frontpage
Human Health
Clinical Studies
Links
Products
Resultat
Animal Health
Clinical Studies
Links
Products
Investor relations
Analys
Annual General Meeting 2006
Annual General Meeting 2007
Annual General Meetings
Articles of Association
Auditors
Calendar
Committees
Corporate Governance
Nomination committee
Option program
Reports
Summary of the Annual General Meeting 2008
Tasks for the Board of Directors
The Board of Directors
The Chairman of the Board
The share
Work plan for the Board of Directors
Ägare
Pages
About Oasmia
Animal Health
Board of Directors
Contact information
Department Directors
Dictionary
For patients
For pet owners
For physicians
For veterinarians
History
Human Health
Investor Relations
Job vacancies
Management
Media contact
Organization
Production
Research and development
Vanliga frågor
Visions & goals
Press releases
“Jackpot in sight for Oasmia”
Call to Extraordinary Genral Meeting
Communiqué from Annual General Meeting
Communiqué from Extraordinary General Meeting
FDA grants Expedited Review Status to Paclical Vet
FDA grants Paclical® Orphan Drug Designation
Final advice for Paclical Phase III program
Great interest for Oasmia in Budapest
Interim report May 1 - July 31 2009
Interim report May 1, 2009 - January 31, 2010
Interim Report May 2008 - January 2009
Last patient out for Paccal® Vet Phase III study
New drug for treatment of cancer in dog
New license agreement with Orion Corporation
Notice of Annual General Meeting
Notice of Annual General Meeting 2009
Oasmia aims for global registration of Paccal Vet
Oasmia announces distribution agreement
Oasmia announces license agreement with Abbott
Oasmia announces licensing agreement
Oasmia appoints market maker
Oasmia carries out private placement
Oasmia changes marketplace
Oasmia changes report publication date
OASMIA confirms Orphan Drug Designation
Oasmia expands license agreement for Paclical Vet
Oasmia in Barcelona
Oasmia obtains Orphan Drug designation
Oasmia presented in Florida
Oasmia presents in Budapest
Oasmia presents in USA
Oasmia presents Phase III-results in Denmark
Oasmia proposes new share issue
Oasmia publishes Interim Report for May - Oct
Oasmia publishes Listing Prospectus
Oasmia publishes prospectus
Oasmia SA’s commitment in rights issue
Oasmia starts clinical studies with Doxophos® Vet
Oasmia successfully concludes enrolment
Oasmia to NGM Equity
Oasmia: FDA grants Paccal Vet Minor Use status
Oasmia’s rights issue fully subscribed
Phase III results presented in Copenhagen
Phase III study generates great interest in Europe
Promising clinical results for Paclical
Solid scientific evidence for Paccal Vet
Status – listing of Oasmia
Unique results for cancer drug
Very good clinical results for Paclical®
Information from Oasmia
Prize to Oasmia
